DBAC DBAC DBAC DBAC
  • Dansk BørneAstma Center
    • Om DBAC
    • Beliggenhed
    • Fonde og donationer
    • Persondatapolitik
  • Børneastma
    • Generelt om astma hos børn
    • Asthma hos små børn
    • Astma hos større børn
    • Generel astma behandling
    • Astmabehandling småbørn
    • Astmabehandling større børn
    • Undersøgelser
    • Gode råd
    • Litteratur til forældre
  • Allergi og eksem
    • Generelt om allergi
    • Mælkeallergi
    • Generelt om eksem
  • Kliniske studier
    • COPSAC 2010 (ABC)
    • COPSAC-Severe
    • COPSAC Acute (Antibiotika)
  • Video

Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.

    Home Publications Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.
    NextPrevious

    Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.

    By Dansk Børne Astma Center | Publications | Comments are Closed | 11 september, 2003 | 0

    Ann Allergy Asthma Immunol. 2003 Sep
    Buchvald F, Bisgaard H.

    Abstract
    BACKGROUND:
    Inhaled, long-acting beta2-agonists or antileukotrienes are alternatives as add-on therapy for asthmatic children taking regular inhaled steroids. Any complementary effects would be relevant to the choice between these alternatives. Exhaled nitric oxide (FeNO) may reflect these effects.

    OBJECTIVE:
    To compare the control of FeNO provided by salmeterol or montelukast add-on therapy in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 microg of budesonide.

    METHODS:
    The study included children with increased FeNO despite regular treatment with budesonide, 400 microg/d, and normal lung function. Montelukast, 5 mg/d, salmeterol, 50 microg twice daily, or placebo was compared as add-on therapy to budesonide, 400 microg, in a randomized, double-blind, double-dummy, crossover study.

    RESULTS:
    Twenty-two children completed the trial. The geometric mean FeNO level was 20 ppb (95% confidence interval [CI], 15-27 ppb) after salmeterol, which was significantly higher than after montelukast (mean, 15 ppb; 95% CI, 11-18 ppb; P = 0.002) and placebo (mean, 15 ppb; 95% CI, 10-21 ppb; P = 0.03). There was no difference in FeNO between the montelukast and placebo groups. Mean forced expiratory volume in 1 second (FEV1) was significantly increased after salmeterol (mean, 2.63 L; 95% CI, 2.34-2.91 L) compared with placebo (mean, 2.48 L; 95% CI, 2.19-2.77 L). Montelukast (mean, 2.57 L; 95% CI, 2.33-2.80 L) was no different than placebo.

    CONCLUSIONS:
    The FeNO levels were significantly higher after salmeterol add-on treatment compared with both placebo and montelukast add-on treatment. Salmeterol significantly improved lung function (FEV1) compared with placebo and nonsignificantly compared with montelukast. Montelukast failed to reduce FeNO and improve lung function compared with placebo in this group of children taking regular budesonide, 400 microg.

    Comment in
    Exhaled nitric oxide. [Ann Allergy Asthma Immunol. 2004]

    PMID: 14533665

    No tags.
    NextPrevious


    KONTAKT

    DBAC
    Dansk BørneAstma Center
    Herlev og Gentofte Hospital
    Telefon +45 3867 7360
    kontakt@dbac.dk
    DBAC • Herlev og Gentofte Hospital • Danmark © 2023
    • 20200227-P4-morgen-Rikke
    • Astma hos skolebørn
    • Astma hos små børn (Bisgaard)
    • COPSAC Acute (Antibiotika)
    • COPSAC informationsaften
    • COPSAC-Severe
    • Dansk BørneAstma Center
      • ABC-DK
      • Forebyggelse
      • Forskning
      • Forskningscentre
      • Generelt om allergi
      • Generelt om eksem
      • Input fra COPSAC familier
      • Knud har tabt pusten
      • Metoder
      • Nyheder
      • Om astma
        • Generel astma behandling
          • Astmabehandling småbørn
          • Behandling af astma hos større børn
        • Generelt om astma hos børn
          • Asthma hos små børn
          • Astma hos større børn
        • Gode råd
        • Undersøgelser
      • Om DBAC
        • Beliggenhed
        • Bestyrelsen
        • Fonde
        • Hjælp os med at hjælpe
        • Jobs
        • Kontakt
        • Litteratur til forældre
        • Patient- og lægeorganisationer
        • Persondatapolitik
        • Sponsorer
      • Spil
      • Undersøgelser
      • video
    • FAVORIT
    • Forebyggelse af astma hos børn (TEST-tilmelding)
    • Forebyggelse af astma hos børn (TEST)
    • Hans Bisgaard
    • Hans Bisgaard nekrolog
    • Indeklima og sundhed på Bellahøj
    • Lokale steroider for børn med astma
    • Mælkeallergi
    • myter og fakta om børneastma
    • Persondatapolitik
    DBAC